Takeda Global Research & Development Center, Inc. Names Dr. Mehmood Khan President
Posted on: Friday, 19 January 2007, 15:00 CST
DEERFIELD, Ill., Jan. 19 /PRNewswire/ -- Takeda Global Research & Development Center, Inc. announced that Mehmood Khan, M.D., has been named president, reporting to Dr. Masaomi Miyamoto, general manager, pharmaceutical development division, Takeda Pharmaceutical Company Limited. Formerly senior vice president of medical and scientific affairs for Takeda Pharmaceuticals North America, Inc., Dr. Khan replaces Dr. John Yates as president.
Established in January 2004, Takeda Global Research & Development Center, Inc. integrated the clinical development activity of the Takeda Pharmaceuticals North America, Inc. research and development group and Takeda's European research and development operation into one organization. The organization's mission is to develop new product candidates, to conduct post-marketing clinical studies and identify and develop innovative lifecycle management approaches for marketed drugs.
"We are extremely pleased that Dr. Mehmood Khan is joining Takeda Global Research & Development Center, Inc. as president. Dr. Khan is a proven leader who brings a wealth of both academic and clinical experience to this role," said Dr. Masaomi Miyamoto, general manager, pharmaceutical development division, Takeda Pharmaceutical Company Limited. "Dr. Khan's familiarity with Takeda's global operations and his expertise in patient care will be invaluable as we work toward identifying and developing new approaches to unmet patient needs through new product candidates and successful post-marketing clinical studies."
Dr. Khan joined Takeda in January 2003 as vice president, medical and scientific affairs from the Mayo Clinic in Rochester, Minn., where he served as consultant physician in Endocrinology and director of the Diabetes, Endocrine and Nutrition Clinical Trials Unit in Mayo's division of endocrinology. At Takeda, Dr. Khan was responsible for leading all aspects of medical and scientific affairs for all of Takeda's marketed products in the United States.
Takeda's medical and scientific affairs department comprises several functions including medical affairs, medical services, education and scientific affairs, clinical and scientific publications and regional scientific managers.
During his tenure, Dr. Khan also directed the department's support of launch and market entries of ROZEREM(TM) (ramelteon), AMITIZA(TM) (lubiprostone) and ACTOS(R) (pioglitazone HCl) combination products; the expanded presence of Regional Scientific Managers; the development of strategic publications plans across all therapeutic areas, as well as implemented non-promotional education grants program in accordance with industry guidelines, and formalized outcomes research function to support and communicate therapeutic value throughout the product lifecycle.
Dr. Khan earned his medical degree from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology in the Department of Medicine, University of Minnesota, Minneapolis. He also has served on numerous state and national committees of the American Diabetes Association, the Minneapolis Medical Research Foundation and the National Institutes of Health. Additionally, he held several visiting professorships, has published extensively and presented at many medical meetings.
Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets products for oral diabetes, insomnia, wakefulness and gastroenterology. Through the Takeda Global Research & Development Center, Inc. the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com/ and http://www.tgrd.com/ .
Takeda Pharmaceuticals North America, Inc.; Takeda Global Research &
CONTACT: Jocelyn M. Gerst of Takeda Global Research & DevelopmentCenter, Inc., +1-224-554-5542, jgerst@tpna.com
Web site: http://www.tpna.com/http://www.tgrd.com/
Source: PRNewswire
Related Articles
- Pfizer Names New SVP of Clinical Development and Medical Affairs for Oncology
- Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit
- MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affairs
- Noven Names Joel Lippman, M.D. As Vice President - Clinical Development & Chief Medical Officer
- Jamie Freedman, M.D., Ph.D. Joins Locus Pharmaceuticals As Chief Medical Officer and Vice President, Clinical Research & Regulatory Affairs
- Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
- NovaShunt AG, a Medical Device Company Focused on Implantable Fluid Management Systems, Appoints Fiona Sander, MSME, As Director of Research & Clinical Affairs
- Voyager Pharmaceutical Corporation Announces the Formation of Its Medical And Scientific Advisory Board
- Anadys Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
- New River Pharmaceuticals to Present Clinical Data on NRP290 at Merrill Lynch Global Pharmaceutical Conference
 |
 |
User Comments (0)
RSS Feeds